CompaniesInnate Pharma
Innate Pharma logo

Innate Pharma

active
Marseille, France
Founded 1999
Website
About

Monoclonal Antibodies

Areas of Focus

Categories

Biologics & BiopharmaceuticalAntibody
Team (10)
Claire de SAINT BLANQUAT
Claire de SAINT BLANQUAT
Vice President, Legal and Corporate Affairs and Secretary of the Supervisory Board
Innate Pharma
executive
Eric VIVIER, DVM, PhD
Eric VIVIER, DVM, PhD
Senior Vice President, Chief Scientific Officer
Innate Pharma
executive
FRÉDÉRIC LOMBARD, MBA
FRÉDÉRIC LOMBARD, MBA
Senior Vice President, Chief Financial Officer
Innate Pharma
executive
Jonathan DICKINSON, MBA, BSc
Jonathan DICKINSON, MBA, BSc
Chief Executive Officer
Innate Pharma
executive
Nicola BELTRAMINELLI, PhD
Nicola BELTRAMINELLI, PhD
Vice President, Chief Development Officer
Innate Pharma
executive
Odile BELZUNCE
Odile BELZUNCE
Vice President Compliance & Operations
Innate Pharma
executive
View all 10 team members →
Clinical Trials (28)
View all

Total Trials

28

As Lead Sponsor

17

As Collaborator

11

Total Enrollment

3,144

By Phase

PHASE1: 12PHASE1/PHASE2: 5PHASE2: 7PHASE3: 1NA: 1

By Status

COMPLETED: 14RECRUITING: 5TERMINATED: 4ACTIVE_NOT_RECRUITING: 2UNKNOWN: 2WITHDRAWN: 1
Clinical Trials Pipeline28 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
NCT01256073
NCT01687387
NCT02459301
NCT02593045
NCT02557516
NCT02643550
NCT03015038
NCT03902184
NCT04590963
NCT04984837
NCT05143970
NCT06088654
NCT06781983
Hover over trial bars to see details

Recent Trials

NCT06781983Lead Sponsor
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
PHASE1Recruiting
105 participants
Started: Jan 24, 2025 · Completed: Apr 30, 2029
NCT06088654Lead Sponsor
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
PHASE1/PHASE2Recruiting
184 participants
Started: Mar 4, 2024 · Completed: Dec 31, 2028
NCT05742607Lead Sponsor
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
PHASE2Recruiting
70 participants
Started: Jun 23, 2023 · Completed: Sep 30, 2026
NCT05321147Lead Sponsor
Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2
PHASE1Completed
20 participants
Started: Mar 17, 2022 · Completed: Feb 8, 2024
NCT05143970Collaborator
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
PHASE1Recruiting
27 participants
Started: Jan 21, 2022 · Completed: Feb 28, 2026
View all 28 trials →
Locations (1)
Headquarters
Marseille, France
Map

Loading map...